ME03462B - NOVI 2' l/ILl 5' DERIVATI 3'-DEOKSI ADENOZINA SUPSTITUISANI AMINOKISELINSKIM ESTROM FOSFORAMIDATA, KAO ANTIKANCERSKA JEDINJENJA - Google Patents

NOVI 2' l/ILl 5' DERIVATI 3'-DEOKSI ADENOZINA SUPSTITUISANI AMINOKISELINSKIM ESTROM FOSFORAMIDATA, KAO ANTIKANCERSKA JEDINJENJA

Info

Publication number
ME03462B
ME03462B MEP-2019-230A MEP2019230A ME03462B ME 03462 B ME03462 B ME 03462B ME P2019230 A MEP2019230 A ME P2019230A ME 03462 B ME03462 B ME 03462B
Authority
ME
Montenegro
Prior art keywords
esterphosphoramidate
new
amino acid
cancer compounds
deoxyadenosine derivatives
Prior art date
Application number
MEP-2019-230A
Other languages
German (de)
English (en)
French (fr)
Inventor
Hugh Griffith
Christopher Mcguigan
Valentina Ferrari
Michaela Serpi
Antunez Carmen Jimenez
Original Assignee
NuCana plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54771155&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME03462(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1421211.2A external-priority patent/GB201421211D0/en
Priority claimed from GBGB1519316.2A external-priority patent/GB201519316D0/en
Application filed by NuCana plc filed Critical NuCana plc
Publication of ME03462B publication Critical patent/ME03462B/me

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/173Purine radicals with 2-deoxyribosyl as the saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16Purine radicals
    • C07H19/20Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
MEP-2019-230A 2014-11-28 2015-11-27 NOVI 2' l/ILl 5' DERIVATI 3'-DEOKSI ADENOZINA SUPSTITUISANI AMINOKISELINSKIM ESTROM FOSFORAMIDATA, KAO ANTIKANCERSKA JEDINJENJA ME03462B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1421211.2A GB201421211D0 (en) 2014-11-28 2014-11-28 Chemical compounds
GBGB1519316.2A GB201519316D0 (en) 2015-11-02 2015-11-02 Chemical compounds
PCT/GB2015/053628 WO2016083830A1 (en) 2014-11-28 2015-11-27 New 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds
EP15804216.8A EP3224268B1 (en) 2014-11-28 2015-11-27 New 2' and/or 5' amino-acid ester phosphoramidate 3'-deoxy adenosine derivatives as anti-cancer compounds

Publications (1)

Publication Number Publication Date
ME03462B true ME03462B (me) 2020-01-20

Family

ID=54771155

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2019-230A ME03462B (me) 2014-11-28 2015-11-27 NOVI 2' l/ILl 5' DERIVATI 3'-DEOKSI ADENOZINA SUPSTITUISANI AMINOKISELINSKIM ESTROM FOSFORAMIDATA, KAO ANTIKANCERSKA JEDINJENJA

Country Status (26)

Country Link
US (3) US10570168B2 (me)
EP (2) EP3224268B1 (me)
JP (2) JP6646668B2 (me)
KR (2) KR102548806B1 (me)
CN (2) CN111909231B (me)
AU (2) AU2015352203B2 (me)
CA (1) CA2962373C (me)
CL (1) CL2017001336A1 (me)
CY (1) CY1122074T1 (me)
DK (1) DK3224268T3 (me)
EA (1) EA031727B1 (me)
ES (1) ES2742167T3 (me)
HR (1) HRP20191461T1 (me)
HU (1) HUE046850T2 (me)
IL (4) IL291927A (me)
LT (1) LT3224268T (me)
ME (1) ME03462B (me)
MX (3) MX394059B (me)
PH (1) PH12017500944B1 (me)
PL (1) PL3224268T3 (me)
PT (1) PT3224268T (me)
RS (1) RS59264B1 (me)
SG (2) SG10202009020VA (me)
SI (1) SI3224268T1 (me)
SM (1) SMT201900489T1 (me)
WO (1) WO2016083830A1 (me)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2828326C (en) 2011-03-01 2019-05-07 Nucana Biomed Limited Phosphoramidate derivatives of 5 - fluoro - 2' - deoxyuridine for use in the treatment of cancer
US10570168B2 (en) 2014-11-28 2020-02-25 NuCana plc 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti- cancer compounds
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201720279D0 (en) * 2017-12-05 2018-01-17 Nucana Biomed Ltd Anticancer compounds
CN110669088B (zh) * 2018-07-02 2023-03-28 成都阿奇生物医药科技有限公司 N-(2-乙基胺)苯磺酰胺基虫草素衍生物及其制备方法和应用
GB201904544D0 (en) 2019-04-01 2019-05-15 NuCana plc Anticancer compounds
CN111888373A (zh) * 2019-05-05 2020-11-06 上海医药集团股份有限公司 一种虫草素或其药学上可接受的盐的应用
CA3252465A1 (en) 2022-05-12 2023-11-16 NuCana plc CANCER TREATMENT
CN117321066A (zh) * 2022-07-12 2023-12-29 南京工业大学 一种基于虫草素经衍生化具有抗肿瘤效应的化合物
CN115181148B (zh) * 2022-07-12 2023-07-14 南京工业大学 一种基于虫草素经衍生化具有抗肿瘤效应的化合物
WO2025058573A1 (en) * 2023-09-15 2025-03-20 National Science And Technology Development Agency Cordycepin derivatives or a pharmaceutically acceptable salt thereof as pan-antiviral agents

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4357324A (en) 1981-02-24 1982-11-02 The United States Of America As Represented By The Department Of Health And Human Services Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine
GB0317009D0 (en) * 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
EP1827460A4 (en) * 2004-12-09 2012-03-14 Univ Minnesota NUCLEOSIDE WITH ANTIVIRAL AND ANTI-CANCER EFFECT
GB0505781D0 (en) 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
WO2006121820A1 (en) * 2005-05-05 2006-11-16 Valeant Research & Development Phosphoramidate prodrugs for treatment of viral infection
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
WO2010081082A2 (en) 2009-01-09 2010-07-15 University College Of Cardiff Consultants Limited Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections
CA2751458C (en) 2009-02-06 2018-06-05 Rfs Pharma, Llc Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections
WO2010108140A1 (en) * 2009-03-20 2010-09-23 Alios Biopharma, Inc. Substituted nucleoside and nucleotide analogs
PT2596004E (pt) 2010-07-19 2014-11-28 Gilead Sciences Inc Métodos para a preparação de pró-fármacos de fosforamidato diastereomericamente puros
WO2012040126A1 (en) * 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
CN105061534A (zh) 2010-09-22 2015-11-18 艾丽奥斯生物制药有限公司 取代的核苷酸类似物
GB201016855D0 (en) 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
CA2828326C (en) 2011-03-01 2019-05-07 Nucana Biomed Limited Phosphoramidate derivatives of 5 - fluoro - 2' - deoxyuridine for use in the treatment of cancer
EP2776438A4 (en) * 2011-11-10 2015-04-29 Inhibitex Inc SUBSTITUTED PURIN NUCLEOSIDES, PHOSPHORAMIDATE AND PHOSPHORDIAMIDATE DERIVATIVES FOR THE TREATMENT OF VIRUS INFECTIONS
SI3043803T1 (sl) 2013-09-11 2022-09-30 Emory University Nukleotidne in nukleozidne sestave in njihova uporaba
KR20160099090A (ko) 2013-11-27 2016-08-19 아이데닉스 파마슈티칼스 엘엘씨 간암의 치료를 위한 뉴클레오티드
BR112016025787B1 (pt) 2014-06-25 2022-12-13 NuCana plc Formulação farmacêutica compreendendo gencitabina-[fenil- (benzóxi-l-alaninil)]-fosfato, seu uso no tratamento de câncer, método de preparação e kit compreendendo a mesma
CN105646629A (zh) 2014-11-25 2016-06-08 广州市恒诺康医药科技有限公司 L-核苷类化合物及其应用
US10570168B2 (en) 2014-11-28 2020-02-25 NuCana plc 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti- cancer compounds
WO2016145142A1 (en) 2015-03-10 2016-09-15 Emory University Nucleotide and nucleoside therapeutics compositions and uses related thereto
DK3197456T3 (en) 2015-05-14 2018-06-06 NuCana plc CANCER TREATMENTS
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
GB201609602D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Chemical compounds
GB201609601D0 (en) 2016-06-01 2016-07-13 Nucana Biomed Ltd Phosphoramidate compounds
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
GB201720279D0 (en) 2017-12-05 2018-01-17 Nucana Biomed Ltd Anticancer compounds

Also Published As

Publication number Publication date
SG10202009020VA (en) 2020-10-29
CA2962373A1 (en) 2016-06-02
MX2017006942A (es) 2017-08-24
AU2015352203B2 (en) 2019-08-15
EA031727B1 (ru) 2019-02-28
AU2019232929A1 (en) 2019-10-10
EP3224268A1 (en) 2017-10-04
KR102741202B1 (ko) 2024-12-19
ES2742167T3 (es) 2020-02-13
SMT201900489T1 (it) 2019-11-13
US20220306675A1 (en) 2022-09-29
IL276109A (en) 2020-08-31
CN111909231B (zh) 2025-10-17
EP3683225A1 (en) 2020-07-22
JP2020075928A (ja) 2020-05-21
IL292062B2 (en) 2023-06-01
CL2017001336A1 (es) 2017-12-15
IL276109B (en) 2022-05-01
PH12017500944A1 (en) 2017-11-20
CN111909231A (zh) 2020-11-10
KR102548806B1 (ko) 2023-06-27
WO2016083830A1 (en) 2016-06-02
MX2020010375A (es) 2022-07-19
US11352387B2 (en) 2022-06-07
NZ767066A (en) 2022-03-25
HUE046850T2 (hu) 2020-03-30
JP6978524B2 (ja) 2021-12-08
IL292062A (en) 2022-06-01
DK3224268T3 (da) 2019-09-02
IL291927A (en) 2022-06-01
PL3224268T3 (pl) 2019-11-29
IL251353A0 (en) 2017-05-29
SG11201702369UA (en) 2017-04-27
US10570168B2 (en) 2020-02-25
MX394059B (es) 2025-03-24
US20170253629A1 (en) 2017-09-07
EA201791182A1 (ru) 2017-09-29
JP6646668B2 (ja) 2020-02-14
PH12017500944B1 (en) 2023-03-08
CN107207554A (zh) 2017-09-26
RS59264B1 (sr) 2019-10-31
PT3224268T (pt) 2019-09-04
KR20170087465A (ko) 2017-07-28
AU2015352203A1 (en) 2017-04-27
KR20230098915A (ko) 2023-07-04
HRP20191461T1 (hr) 2019-11-15
CN107207554B (zh) 2020-09-11
MX375759B (es) 2025-03-06
EP3224268B1 (en) 2019-06-26
IL251353B (en) 2020-08-31
US20200181189A1 (en) 2020-06-11
LT3224268T (lt) 2019-09-25
BR112017011187A2 (pt) 2018-01-02
SI3224268T1 (sl) 2019-10-30
NZ730919A (en) 2021-02-26
AU2019232929B2 (en) 2020-09-10
CA2962373C (en) 2023-04-25
US12054510B2 (en) 2024-08-06
CY1122074T1 (el) 2020-11-25
MX2022008744A (es) 2022-07-27
JP2017535587A (ja) 2017-11-30

Similar Documents

Publication Publication Date Title
ME03462B (me) NOVI 2' l/ILl 5' DERIVATI 3'-DEOKSI ADENOZINA SUPSTITUISANI AMINOKISELINSKIM ESTROM FOSFORAMIDATA, KAO ANTIKANCERSKA JEDINJENJA
IL256600B (en) Pyridine compounds useful for combating phytopathogenic fungi
GB201609467D0 (en) Improvements in or relating to organic compounds
GB201510940D0 (en) Improvements in or relating to organic compounds
GB201615581D0 (en) Improvements in or relating to organic compounds
GB201504385D0 (en) Improvements in or relating to organic compounds
GB201620044D0 (en) Improvements in or relating to organic compounds
GB201604969D0 (en) Improvements in or relating to organic compounds
ZA201900415B (en) Improvements in or relating to organic compounds
ZA201802697B (en) Improvements in or relating to organic compounds
GB201516313D0 (en) Improvements in or relating to organic compounds
GB201604970D0 (en) Improvements in or relating to organic compounds
GB201615622D0 (en) Improvements in or relating to organic compounds
GB201516396D0 (en) Improvements in or relating to organic compounds
FI20155150L (fi) Koostumus krapulan oireiden ehkäisemiseksi
PL3515589T3 (pl) Ulepszenia w związkach organicznych lub odnoszące się do związków organicznych
EP3416502A4 (en) GLYCEMIC REDUCTION COMPOSITION
GB201521861D0 (en) Improvements in or relating to organic compounds
GB201621887D0 (en) Improvements in or relating to organic compounds
GB201510942D0 (en) Improvements in or relating to organic compounds
DK3169322T3 (da) Diætetisk sammensætning med antidyslipidemisk aktivitet
GB201614408D0 (en) Improvements in or relating to organic compounds
GB201515141D0 (en) Improvements in or relating to organic compounds
GB201601133D0 (en) Improvements in or relating to organic compounds
GB201522422D0 (en) Improvements in or relating to organic compounds